Observational studyThe Lancet. Respiratory medicine2022
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study.
Observational study in The Lancet. Respiratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05736939 (Gender Differences in the Recovery Rate Following a Hybrid Pulmonary Rehabilitation Programme in Patients With Long COVID-19 Syndrome), which is not on this map. Cited by 261 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gender Differences in the Recovery Rate Following a Hybrid Pulmonary Rehabilitation Programme in Patients With Long COVID-19 Syndrome
Who cites it
261 citing papers in PubMed, 15 syntheses or guidelines pooled it.
- Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.Medicine · 2026Pooled it
- Risk factors for post-COVID-19 condition among previously hospitalized COVID-19 patients: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Health-related quality of life in COVID-19 patients: a systematic review and meta-analysis of EQ-5D studies.Health and quality of life outcomes · 2025Pooled it
- Symptom Trajectories and Clinical Subtypes in Post-COVID-19 Condition: Systematic Review and Clustering Analysis.JMIR public health and surveillance · 2025Pooled it
- The effect of dietary weight-loss interventions on the inflammatory markers interleukin-6 and TNF-alpha in adults with obesity: A systematic review and meta-analysis of randomized controlled clinical trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- The risk of Long Covid symptoms: a systematic review and meta-analysis of controlled studies.Nature communications · 2025Pooled it
- Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Pooled it
- Neurocognitive Impairment in Long COVID: A Systematic Review.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025Pooled it
- Functional Recovery of Adults Following Acute COVID-19: A Systematic Review and Meta-Analysis.Physical therapy · 2025Pooled it
- The impact of long COVID on physical and cardiorespiratory parameters: A systematic review.PloS one · 2025Pooled it
- Pooled it
- Long COVID among people with HIV: A systematic review and meta-analysis.HIV medicine · 2025Pooled it
- Cognitive domains affected post-COVID-19; a systematic review and meta-analysis.European journal of neurology · 2025Pooled it
- Performance of artificial intelligence in predicting the prognossis of severe COVID-19: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.International journal of antimicrobial agents · 2023Pooled it
- Dexmedetomidine for sedation during noninvasive ventilation in COVID-19 patients from the Helmet-COVID randomized clinical trial post-hoc analysis.Scientific reports · 2026Trial
- Cost-effectiveness of the ReDIRECT/counterweight-plus weight management programme to alleviate symptoms of long COVID.Nature communications · 2025Trial
- Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.Nature communications · 2025Trial
- Potential Diaphragm Muscle Weakness-related Dyspnea Persists 2 Years after COVID-19 and Could Be Improved by Inspiratory Muscle Training: Results of an Observational and an Interventional Clinical Trial.American journal of respiratory and critical care medicine · 2024Trial
- Additive benefit of rehabilitation on physical status, symptoms and mental health after hospitalisation for severe COVID-19 pneumonia.BMJ open respiratory research · 2023Trial
201 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
1 author.
Funding
Abstract
backgroundNo effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge.
methodsThe Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing.
findings2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7-9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46-0·99]), obesity (0·50 [0·34-0·74]) and invasive mechanical ventilation (0·42 [0·23-0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74-1·00]), at 5 months (0·74 [0·64-0·88]) to 1 year (0·75 [0·62-0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters.
interpretationThe sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials.
fundingUK Research and Innovation and National Institute for Health Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.